Apo-2DcR
AssigneeGenentech, Inc.
InventorsAvi J. Ashkenazi, Kevin P. Baker, Austin Gurney, William I. Wood
Life of this patent
Estimating the term…
Abstract
Novel polypeptides, designated Apo-2DcR, which are capable of binding Apo-2 ligand are provided. Compositions including Apo-2DcR chimeras, nucleic acid encoding Apo-2DcR, and antibodies to Apo-2DcR are also provided.
Claims29
Isolated Apo-2DcR polypeptide having at least about 80% amino acid sequence identity with native sequence Apo-2DcR polypeptide comprising amino acid residues 1 to 259 of FIG. 1A (SEQ ID NO:
- 1).
Isolated native sequence Apo-2DcR polypeptide comprising amino acid residues 1 to 259 of FIG. 1A (SEQ ID NO:
- 1).
Isolated extracellular domain sequence of Apo-2DcR polypeptide comprising amino acid residues 1 to 161 of FIG. 1A (SEQ ID NO:
- 1).
Isolated native sequence Apo-2DcR polypeptide comprising amino acid residues −40 to 259 of FIG. 1B (SEQ ID NO:
- 3).
A non-human, transgenic animal which contains cells that express nucleic acid encoding Apo-2DcR polypeptide.
A non-human, knockout animal which contains cells having an altered gene encoding Apo-2DcR polypeptide.
An article of manufacture, comprising a container and a composition contained within said container, wherein the composition includes Apo-2DcR polypeptide or Apo-2DcR antibodies.
A method of modulating apoptosis in mammalian cells comprising exposing said cells to Apo-2DcR polypeptide.
Dependencies are inferred from the claim text.